罗格列酮对2型糖尿病大鼠肾脏ERK/c-fos蛋白表达的影响

摘要

目的 观察罗格列酮对糖尿病大鼠肾脏细胞外信号调节激酶(ERK)、c-fos蛋白表达的影响.方法 应用高糖高脂饮食加小剂量链脲佐菌素建立2型糖尿病大鼠模型,用免疫组化方法检测肾脏ERK、c-fos蛋白表达.结果:(1)成模动物具有高血糖、胰岛素抵抗、肾脏病变等特点.(2)糖尿病组大鼠肾组织中ERK、c-fos表达较对照组明显增加.罗格列酮治疗后ERK、c-fos活性降低,肾功能及组织病理学损害改善.结论 2型糖尿病大鼠模型肾组织ERK/c-fos蛋白表达增加.罗格列酮治疗后ERK/c-fos表达降低,伴肾功能和肾脏病理损害改善.%Objective To investigate the effect of rosiglitazone on activation of renal ERK and c-fos in the experimental type 2 diabetic rats. Methods The rats of model groups were intraperitoneally given low-dose streptozotocin (STZ) after taking the sucrose-and fat-rich diets for one month.Immunohistochemistry and computer image-pattern analysis system were used to analyze expression of ERK and c-fos in renal tissues. Results (1)This rat model of type 2 diabetes mellitus showed hyperglycemia, IR and typical renal lesions. (2)Compared to normal group, the protein expression of ERK and c-fos were increased in glomeruli of type 2 diabetic rats. Rosiglitazone inhibited significantly the activation of ERK and c-fos, partly improved the renal function and matrix accumulation. Conclusions (1) A rat model with type 2 diabetes mellitus presents the increased protein expression of ERK and c-fos of diabetic nephropathy. (2) The kidney protection of rosiglitazone is associated, at least in part, with down-regulating ERK/c-fos activation in renal tissues.